Recent Company News

• 02:01 AM ET Apr 25, 2026
  

  StreetAccount Sector Summary - Healthcare Weekly Recap

• 01:50 PM ET Apr 24, 2026
  

  Stifel comments on the latest CNPV vouchers; identifies winners and remains upbeat on others

• 10:43 AM ET Apr 24, 2026
  

  Compass Pathways issues press release on FDA issuance of CNPV voucher and FDA granting NDA rolling review request ($8.99, -0.16)

• 09:56 AM ET Apr 24, 2026
  

  FDA issues three CNPV vouchers to accelerate development of psychedelic medications for mental illness

• 08:53 AM ET Apr 24, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 08:43 PM ET Apr 23, 2026
  

  Compass Pathways initiated buy at B Riley Securities ($9.15, 0.00)

• 05:59 PM ET Apr 20, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 11:37 AM ET Apr 22, 2026
  

  StreetAccount ESG Research Round Up

• 06:35 AM ET Apr 21, 2026
  

  Compass Pathways collaborates with Osmind to advance Independent clinic readiness for psychedelic treatments ($9.46, 0.00)